Clinical Trial Update: Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study [Phase 4]

View source ↗

Summary

Phase 4 open-label study assessing the long-term safety and tolerability of a migraine therapy in migraine patients. Results were posted in February 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Migraine, Migraine Disorders | Phase 4 | Status: COMPLETED | Results posted: 2024-02-06